

Figure S1. A screening was performed to identify compounds with >50% inhibition of SLY protein hemolysis at a concentration of 64 $\mu\text{g/mL}$




Figure S2. Safety assessment of Canagliflozin. (A) Cytotoxicity of canagliflozin for RAW264.7 *** $p < 0.001$ vs. 0 $\mu\text{g/mL}$; (B) Hemolytic activity of ampicillin to the RBCs in the absence or presence of canagliflozin; To evaluate Ampicillin cytotoxicity in Vero (C) and RAW264.7 cells (D) in presence of canagliflozin.